BioGenes and Eurofins BioPharma Product Testing Munich
News Jun 04, 2016
BioGenes GmbH, a global leader in host cell protein (HCP) assay development, has entered into a collaboration with Eurofins BioPharma Product Testing Munich (Eurofins Munich), an internationally renowned Contract Research Organization for (bio)pharmaceutical product-testing and Centre of Excellence for Bioassays, to serve as its preferred partner for HCP related impurity testing.
BioGenes will provide generic 360-HCP kits and specific HCP assay development services as well as related 2D electrophoresis (2D-DIGE) and concomitant antibody preparation. Eurofins Munich will provide complementary analytical services to BioGenes spanning the complete product development cycle from lead discovery to late stage clinical development.
Eurofins BioPharma Product Testing Munich GmbH, in cooperation with BSL Bioservice Scientific Laboratories Munich GmbH, supports its clients especially in the fields of bioassays, microbiology, in vitro toxicology, pharmacology, and biocompatibility. Immunoanalytical and bioanalytical studies are offered as support of non-clinical and clinical programs. Eurofins BioPharma Product Testing covers the whole range from standardized tests to special requirements and tailor-made studies.
With a strong dedication to quality and customer service since its foundation in 1992, BioGenes is the trusted and experienced immunoassay expert and a well-respected partner for leading pharmaceutical and biotech companies worldwide.
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE